Endurant Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Endurant Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,650	Closed	-$448K	–	4
2023 Q4	$448K	Sell	4,650 -174,918	-97%	-$15.5M	2.57%	14
2023 Q3	$15.9M	Buy	179,568 +135,966	+312%	+$12.1M	14.27%	1
2023 Q2	$3.78M	Sell	43,602 -212,014	-83%	-$20M	3.3%	10
2023 Q1	$24.9M	Buy	255,616 +171,259	+203%	+$17.8M	12.77%	1
2022 Q4	$8.73M	Sell	84,357 -61,017	-42%	-$5.73M	3.55%	9
2022 Q3	$12.3M	Buy	145,374 +119,399	+460%	+$10.6M	4.01%	8
2022 Q2	$2.15M	Buy	+25,975	New	+$2.07M	0.76%	33
2020 Q2	–	Sell	-28,599	Closed	-$2.42M	–	62
2020 Q1	$2.42M	Buy	+28,599	New	+$2.46M	1.1%	25
2018 Q1	–	Sell	-10,100	Closed	-$901K	–	75
2017 Q4	$901K	Buy	+10,100	New	+$878K	0.28%	61
2017 Q3	–	Sell	-9,300	Closed	-$845K	–	88
2017 Q2	$845K	Buy	9,300 +4,200	+82%	+$382K	0.24%	71
2017 Q1	$448K	Buy	+5,100	New	+$454K	0.14%	79

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Endurant Capital Management's BMRN Position: Q1 2024 in Review

Endurant Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 4,650 shares — an estimated $448K sold.

Endurant Capital Management first reported a position in BMRN in Q1 2017 and held it in 11 quarters. The position peaked at $24.9M in Q1 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Endurant Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Endurant Capital Management sold 4,650 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $448K.
Endurant Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 11 quarters.
Endurant Capital Management's BioMarin Pharmaceuticals position peaked at $24.9M in Q1 2023.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Endurant Capital Management's 13F filing for Q1 2024.